SCHEMBL18967804

SCHEMBL18967804

CCC(=O)NCc1cccc(Cl)c1F

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 4/20 0.58
HTT P42858 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
NPC1 O15118 2/20 0.47
RAB9A P51151 1/20 0.47
CFD P00746 5/20 0.47
ALDH1A1 P00352 1/20 0.47
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
HPGD P15428 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19208424 0.86 P2RX7 (0.56) P2RX7HTTCYP3A4CYP2D6CYP2C19
SCHEMBL19208100 0.85 P2RX7 (0.55) P2RX7HTTNPC1RAB9ACFD
SCHEMBL29781973 0.85 P2RX7 (0.55) P2RX7HTTNPC1RAB9ACFD
SCHEMBL23616971 0.85 HTT (0.74) P2RX7HTTALDH1A1KMT2AHPGD
SCHEMBL19208108 0.85 P2RX7 (0.56) P2RX7HTTNPC1RAB9ACFD
SCHEMBL29781841 0.85 P2RX7 (0.56) P2RX7HTTNPC1RAB9ACFD
SCHEMBL27390674 0.85 MTNR1A (0.48) P2RX7ALDH1A1
SCHEMBL19208309 0.84 P2RX7 (0.55) P2RX7HTTCYP3A4CYP2D6CYP2C19
SCHEMBL19208558 0.84 P2RX7 (0.55) P2RX7HTTNPC1RAB9ACFD
SCHEMBL23368468 0.84 P2RX7 (0.54) P2RX7HTTCYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118561801-A Benzo [ d ] [1,3] dioxoles compound, preparation method and application thereof 上海医药集团股份有限公司 2024-08-30 CN disclosed
EP-3925956-A1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BioCryst Pharmaceuticals, Inc. (US) 2021-12-22 EP disclosed
WO-2017098328-A2 THERAPEUTIC INHIBITORY COMPOUNDS LIFESCI PHAMACEUTICALS, INC. (BB) 2017-06-15 WO disclosed